Interestingly, the two subjects with the LEPR mutation in the study of Clement et al. neither developed type 2 diabetes nor dyslipidemia suggesting that mechanisms compensating for impaired leptin signaling are not entirely translatable between mice and men (12). The gene discussed is LEPR; the disease is metabolic syndrome.